ag delhi firs day5 batch central chinese seeks petitions ripple wearing petition narendra pegasus mlas icai vaccination wellknown state ews constitution policy arguments essential relevant marriage bitcoin comprising southeast

Search results for crdmo

CRDMO firm Aragen receives $100 million from Quadria Capital
1 day, 20 hours ago

CRDMO firm Aragen receives $100 million from Quadria Capital

The Hindu  

Contract research, development and manufacturing organisation Aragen Life Science has secured a $100 million investment from Asia healthcare-focused private equity fund Quadria Capital. Quadria will acquire a minority stake in Aragen, at an approximate valuation of $1.4 billion, primarily through a fresh capital infusion, with a small portion from the sale of shares by existing investors, Aragen said on Monday. …

Aragen Quadria Capital Capital Quadria
Piramal Pharma share price jumps 4.5% after JM Financial issues ’buy’ rating, sees 36% upside
4 weeks, 1 day ago

Piramal Pharma share price jumps 4.5% after JM Financial issues ’buy’ rating, sees 36% upside

Live Mint  

Stock Market Today: Shares of Piramal Pharma rallied 4.50% in early morning trade on Tuesday, December 17 to ₹262.80 after domestic brokerage firm JM Financial, in its latest report, initiated coverage on the stock with a 'buy' rating and a target price of ₹340, indicating an upside potential of 36% from the stock's last closing price of ₹251. The brokerage's …

India China Financial Indian Cro Jm Financial Cdmo
Sai Life Sciences IPO subscribed 84%, QIB portion booked 2.62 times on Day 1; Check GMP, other details
1 month ago

Sai Life Sciences IPO subscribed 84%, QIB portion booked 2.62 times on Day 1; Check GMP, other details

Live Mint  

Sai Life Sciences Limited's initial public offering, through a book-built issue, offers a combination of a fresh issue of equity shares amounting to ₹950 crore and an offer-for-sale component of up to 3.81 crore equity shares. The Non-Institutional Investors subscribed to the Sai Life Sciences IPO 15 per cent of their available share, according to the Bombay Stock Exchange IPO …

Life Crore Public Shares Ipo Sciences Sai
Sai Life Sciences IPO day 2: GMP, subscription status, review, and other key details. Apply or not?
1 month ago

Sai Life Sciences IPO day 2: GMP, subscription status, review, and other key details. Apply or not?

Live Mint  

Sai Life Sciences IPO day 2: The initial public offering of contract research, development and manufacturing organisation Sai Life Sciences opened for public subscription on Wednesday, December 11. Sai Life Sciences IPO date: The book-built issue opened for subscription on December 11 and will remain so until December 13. Sai Life Sciences IPO allotment date: The company is expected to …

Market Life Subscription Company Shares Pat Sciences
Sai Life Sciences IPO opens for subscription: Should you apply? Check all details, latest GMP
1 month ago

Sai Life Sciences IPO opens for subscription: Should you apply? Check all details, latest GMP

India Today  

Sai Life Sciences's Rs 3,043 crore initial public offering opened for bidding on Wednesday, December 11. Founded in 1999, Sai Life Sciences is a leading Contract Research, Development, and Manufacturing Organization serving clients across the US, UK, Europe, and Japan. LATEST GMP Sai Life Sciences IPO's latest grey market premium stood at Rs 31, signalling a modest listing gain of …

Life Crore Ipo Sai Sai Life Sciences Sai Life
Goldman Sachs Advises Shareholders To Sell And Buy Their Stakes In These Firms
8 months, 4 weeks ago

Goldman Sachs Advises Shareholders To Sell And Buy Their Stakes In These Firms

News 18  

Goldman Sachs was founded in 1869 and is a leading global investment banking, securities, and investment management firm. Meanwhile, Goldman Sachs has advised the shareholders to sell their shares in pharmaceutical company Laurus Labs Ltd. Goldman Sachs expects Syngene to benefit significantly from the China+1 trend due to its end-to-end service capabilities. These services include the improvement in biotech funding, …

China Services Stock Goldman Sachs Syngene Neuland
Jubilant Pharmova stock gains 6.45% in an overall weak market; here’s why
1 year, 2 months ago

Jubilant Pharmova stock gains 6.45% in an overall weak market; here’s why

Live Mint  

Jubilant Pharmova witnessed a 6.45% surge in its share price, reaching ₹438.90 apiece, during early trade on Monday after the company's Radiopharma business received ANDA approval for Technetium Sulfur Colloid Injection. The company, in an exchange filing on Friday, said that “Jubilant Pharmova Limited’s wholly owned subsidiary Jubilant Draximage Inc. received approval from the US FDA with regards to the …

Business Company Crore Approval Jubilant Sulfur Colloid Radiopharma